Walmart will pay $50 million to settle a federal government lawsuit accusing the nation’s largest retailer of fueling the opioid epidemic through its pharmacies, the Department of Justice announced Friday — a fraction of the billions of dollars in penalties the government had originally said Walmart could owe.
The settlement resolves one of the most significant opioid cases the Justice Department has pursued against a single company, and ends litigation that began in December 2020 during the final weeks of President Donald Trump’s first term.
Walmart did not admit liability. In a regulatory filing, the company called the $50 million payout “immaterial” — a figure that represents a tiny fraction of the $11.7 billion in net income Walmart reported in just the first six months of its current fiscal year.
What the Government Accused Walmart Of
The Department of Justice accused Walmart of repeatedly violating the federal Controlled Substances Act since 2013 by missing clear warning signs of opioid abuse at its pharmacy counters.
Specifically, the government alleged that:
- Walmart pharmacists filled prescriptions from doctors who were operating as “pill mills” — medical offices dispensing opioids without legitimate medical purpose
- Some Walmart compliance officials were aware that certain prescribers were problematic but continued filling their prescriptions anyway
- Walmart failed to track and report suspicious opioid prescriptions to the US Drug Enforcement Administration as required by law
The lawsuit had been one of the government’s biggest actions against a single company over the opioid crisis that has killed more than 905,000 Americans between 1999 and 2025, according to the Centers for Disease Control and Prevention.
How the Case Was Narrowed
The case against Walmart had already been significantly scaled back before the settlement. In March 2024, US District Judge Colm Connolly in Delaware dismissed two of the government’s claims:
- That Walmart failed to report suspicious prescriptions to the DEA
- That Walmart pharmacists failed to document red flags associated with prescriptions
The judge allowed two claims to proceed: that Walmart compliance personnel knew certain prescriptions were invalid yet pharmacists dispensed them anyway, and a related claim that pharmacists themselves knew prescriptions were invalid.
The settlement resolves those remaining claims.
What Walmart Must Change
Beyond the $50 million payment, the settlement includes operational requirements:
- Tighter oversight of pharmacists in dispensing controlled substances
- A dedicated hotline for employees and patients to report suspected illegal dispensing of opioids
Walmart’s Prior Opioid Settlement
This federal settlement is separate from Walmart’s 2022 agreement to pay $3.1 billion to resolve thousands of lawsuits brought by state and local governments over its pharmacies’ role in the opioid crisis — one of the largest opioid settlements by a pharmacy chain.
Other major pharmacy chains reached similar settlements: CVS and Walgreens both agreed to larger payouts than Walmart in separate state-level resolutions.
The Broader Opioid Accountability Picture
The opioid epidemic has generated some of the largest corporate settlements in American legal history:
- Purdue Pharma pleaded guilty to criminal charges in 2020 related to its painkiller OxyContin after filing for bankruptcy
- McKesson, Cardinal Health, and AmerisourceBergen reached a combined $21 billion settlement with states
- Johnson & Johnson paid billions to resolve opioid claims nationally
Annual opioid overdose deaths began declining after 2022, according to the CDC, though experts say the crisis remains far from over.
Walmart said in a statement: “We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care.”
A joint stipulation dismissing the case was filed Thursday in federal court in Wilmington, Delaware.
InjuryWatch News will continue tracking opioid accountability litigation across the country.